Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in adults with moderate-to-severe atopic dermatitis after prior systemic treatment failure
2022-003361-37Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Etrasimod 2 mg once daily with Placebo once daily (2 arms). Primary endpoint: IGA response at Week 16. Started Dec 2022; status: completed.
02
Drugs
etrasimod
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-003361-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003361-37.